Physician profile
Thomas Cawthon
NPI 1336256601
$1,795.34
in general payments reported to CMS, 2019-2025
15 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $390 · 2021: $322 · 2022: $214 · 2023: $250 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $556.97 | 2019-2022 | |
| Optinose US, INC. | $341.23 | 2019-2021 | |
| Abbvie INC. | $248.06 | 2023-2025 | Botox |
| Intersect Ent, INC. | $173.91 | 2019-2021 | |
| Radius Health, INC. | $133.53 | 2025 | Tymlos |
| Novo Nordisk INC | $91.26 | 2025 | Wegovy |
| Medtronic USA, INC. | $69.23 | 2019 | |
| Stryker Corporation | $59.74 | 2019-2021 | |
| Innovation Technologies INC | $28.85 | 2022 | |
| Genzyme Corporation | $17.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.61 | 2019 | |
| Amryt Pharma Holdings LTD | $16.47 | 2021 | |
| Neurent Medical Limited | $15.58 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Galderma Laboratories, L.P. | $13.41 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cawthon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.